A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Simple Search

You could also try: separation (32), discrimination (47), segregation (8), isolation (60)

Gilteritinib

Description
Chemotherapy Protocol Acute Myeloid Leukaemia GILTERITINIB Regimen  AML - Gilteritinib Indication Gilteritinib for treating relapsed/refractory FLT3 mutation positive myelo
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/Gilteritinib.pdf

Darolutamide

Description
Chemotherapy Protocol PROSTATE CANCER DAROLUTAMIDE Regimen • Prostate - Darolutamide Indication • Darolutamide is recommended where the; - patient has a proven hi
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Darolutamide.pdf

Apalutamide v1

Description
Chemotherapy Protocol PROSTATE APALUTAMIDE Regimen  Prostate cancer Indication  Apalutamide is recommended for non-metastatic prostate cancer as defined by recent
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Apalutamide-v1.pdf

Azacitidine5

Description
Chemotherapy Protocol Myelodysplastic Syndrome (MDS) Acute Myeloid Leukaemia (AML) Chronic Myelomonocytic Leukaemia (CMML) Azacitidine SC (
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/Azacitidine5.pdf

Azacitidine5+2Ver1

Description
Chemotherapy Protocol Myelodysplastic Syndrome (MDS) Acute Myeloid Leukaemia (AML) Chronic Myelomonocytic Leukaemia (CMML) Azacitidine SC (5+
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/Azacitidine5-2Ver1.pdf

Handling concerns and complaints policy

Description
Handling Complaints Policy, Version 13.0 Trust reference PET003 Version number 13.0 Description Policy to explain how University Hospital Southampton
Url
/Media/UHS-website-2019/Docs/Policies/Handling-concerns-and-complaints-policy.pdf
1 to 6 of 6